Table 1.
Baseline patient demographics and clinical characteristics.
| Characteristic | Patients N = 26 |
|---|---|
| Median age, years (range) | 61 (39–81) |
| Gender, N (%) | |
| Female | 4 (15) |
| Male | 22 (85) |
| Race, N (%) | |
| Caucasian | 20 (77) |
| Asian | 2 (8) |
| African American | 4 (15) |
| Median BMI (range) | 26.3 (19.7–42.3) |
| Median AFP at diagnosis (range) | 29 IU/mL (1–71,929) |
| Received Prior Embolization, N (%) | 17 (65) |
| Received Prior Ablation, N (%) | 9 (35) |
| Received Prior Radiation Therapy, N (%) | 8 (31) |
| Received Prior Systemic Therapy, N (%) | 10 (39) |
| Cirrhosis Present, N (%) | 19 (73) |
| Type II Diabetes Mellitus, N (%) | 11 (42) |
| Hyperlipidemia, N (%) | 10 (39) |
| Alcohol use, N (%) | 8 (31) |
| Hepatitis C, N (%) | 11 (42) |
| Non-Alcoholic Steatohepatitis, N (%) | 2 (8) |
| Child Pugh Score at Diagnosis, N (%) | |
| Missing | 1 |
| A5 | 16 (64) |
| A6 | 7 (28) |
| B7 | 1 (4) |
| B8 | 1 (4) |
| Child Pugh Score at start of Cabozantinib Therapy, N (%) | |
| Missing | 1 |
| A5 | 11 (44) |
| A6 | 7 (28) |
| B7 | 3 (12) |
| B8 | 1 (4) |
| B9 | 3 (12) |
| Total Lines of Therapy Received, N (%) | |
| 2 | 3 (12) |
| 3 | 13 (50) |
| 4 | 6 (23) |
| 5 | 4 (15) |
| Line of Therapy Cabozantinib Received, N (%) | |
| 2 | 4 (15) |
| 3 | 18 (69) |
| 4 | 4 (15) |
| Line of Therapy IO Received, N (%) | |
| 1 | 10 (38) |
| 2 | 15 (58) |
| 3 | 1 (4) |